Fierce Pharma features a discussion with CEO, Bobby Sheng in an article entitled “After Bora’s biologics debut, CEO outlines quest to join ranks of top CDMOs”.
Published on November 10, 2022
Thank you Fierce Pharma and author Fraiser Kansteiner
Bora’s focus on customer partnership is key to Bora’s acquisition strategy. Bora’s recent addition of biologics offerings with acquisition of Eden Biologics is one example. “Bora’s not about recreating the wheel,” Sheng told Fierce Pharma. “Bora’s about finding opportunities and providing something for the customer they don’t have yet.”
Read the full article at: